Literature DB >> 12841295

The vasculopathy of Raynaud's phenomenon and scleroderma.

Nicholas A Flavahan1, Sheila Flavahan, Srabani Mitra, Maqsood A Chotani.   

Abstract

The scleroderma (SSc) disease process involves dramatic dysfunction in acute and chronic vascular regulatory mechanisms; it presents initially with heightened vasoconstrictor or vasospastic activity and progresses to structural derangement or vasculopathy of the microcirculation. This article discusses the regulatory mechanisms that contribute to this dysfunction and the vascular changes in the context of the other aspects of the SSc disease process in a novel attempt to integrate the individual pathologies of the disease process.

Entities:  

Mesh:

Year:  2003        PMID: 12841295     DOI: 10.1016/s0889-857x(03)00021-8

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  21 in total

1.  Cyclic AMP-Rap1A signaling activates RhoA to induce α(2c)-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells.

Authors:  Selvi C Jeyaraj; Nicholas T Unger; Ali H Eid; Srabani Mitra; N Paul El-Dahdah; Lawrence A Quilliam; Nicholas A Flavahan; Maqsood A Chotani
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-23       Impact factor: 4.249

2.  High resolution 3 Tesla contrast-enhanced MR angiography of the hands in Raynaud's disease.

Authors:  J Walcher; R Strecker; S Goldacker; J Winterer; M Langer; T A Bley
Journal:  Clin Rheumatol       Date:  2006-03-15       Impact factor: 2.980

3.  A case of MCTD overlapped by Takayasu's arteritis, presenting Raynaud's phenomenon as the initial manifestation of both diseases.

Authors:  Mie Jin Lim; Seong Ryul Kwon; Sang Gu Kim; Won Park
Journal:  Rheumatol Int       Date:  2008-10-11       Impact factor: 2.631

Review 4.  Intracellular α(2C)-adrenoceptors: storage depot, stunted development or signaling domain?

Authors:  Maqsood A Chotani; Nicholas A Flavahan
Journal:  Biochim Biophys Acta       Date:  2011-05-14

5.  Abnormal fibrillin-1 expression and chronic oxidative stress mediate endothelial mesenchymal transition in a murine model of systemic sclerosis.

Authors:  Hao Xu; Maria Zaidi; Janine Struve; Deron W Jones; John G Krolikowski; Sandhya Nandedkar; Nicole L Lohr; Ashish Gadicherla; Paul S Pagel; Mary Ellen Csuka; Kirkwood A Pritchard; Dorothée Weihrauch
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-15       Impact factor: 4.249

Review 6.  Scleroderma therapy: clinical overview of current trends and future perspective.

Authors:  Afsha A Topal; Rachita S Dhurat
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

Review 7.  Rap1 GTPases: an emerging role in the cardiovasculature.

Authors:  Selvi C Jeyaraj; Nicholas T Unger; Maqsood A Chotani
Journal:  Life Sci       Date:  2011-02-02       Impact factor: 5.037

Review 8.  Systemic sclerosis: a prototypic multisystem fibrotic disorder.

Authors:  John Varga; David Abraham
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

9.  Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study.

Authors:  Paul Bălănescu; Anca Lădaru; Eugenia Bălănescu; Theodor Voiosu; Cristian Băicuş; Gheorghe Andrei Dan
Journal:  J Clin Lab Anal       Date:  2015-09-01       Impact factor: 2.352

10.  Abnormalities in the regulators of angiogenesis in patients with scleroderma.

Authors:  Laura K Hummers; Amy Hall; Fredrick M Wigley; Michael Simons
Journal:  J Rheumatol       Date:  2009-02-17       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.